NCT01384422已完成2 期
Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Galapagos NV
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- The number of patients with an ACR20 score at Week 4 as a measure of efficacy
研究概览
简要总结
- Thirty six patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will be evaluated for improvement of disease activity when taking GLPG0634 or matching placebo for 4 weeks.
- During the course of the study, patients will also be examined for any side effects that may occur, and the amount of GLPG0634 present in the blood as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood will be determined.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have active RA as shown by five or more swollen joints (from the 66-joint count), five or more tender joints (from 68-joint count), and a serum CRP ≥1.0 mg/dL;
- •Have received methotrexate for six months or longer and at a stable dose of 7.5 to 25 mg/week (extremes included) for at least four weeks prior to screening and willing to continue on this regimen for the duration of the study;
- •If taking oral steroids, these should be at a dose ≤10 mg/day of prednisone or prednisone equivalent and stable for at least four weeks prior to screening;
- •If taking non-steroidal anti-inflammatory drugs (NSAIDs), these must be at a stable dose for at least two weeks prior to screening;
- •Female subjects must have a negative pregnancy test unless they are surgically sterile or have been post-menopausal for at least one year (12 consecutive months without menses);
- •Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for at least four weeks after the last dose of study drug. Sexually active men must agree to use a medically acceptable form of contraception during the study and continue its use for at least 3 months after the last dose of study drug; and
- •Able and willing to sign the informed consent prior to screening evaluations and agree to schedule of assessments.
排除标准
- •Treatment with disease-modifying antirheumatic drugs (DMARDs), other than background methotrexate;
- •Current or previous RA treatment with a biological agent, with the exception of biologics administered in a clinical study setting more than six months prior to screening (12 months for rituximab or other B cell depleting agents);
- •Previous treatment at any time with a cytotoxic agent, other than methotrexate, before screening;
- •Receipt of an intra-articular or parenteral corticosteroid injection within four weeks prior to screening;
- •Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator, such as anaphylaxis, requiring hospitalization;
- •Positive serology for human immunodeficiency virus (HIV)1 or 2 or hepatitis B or C, or any history of hepatitis from any cause with the exception of hepatitis A;
- •History of any inflammatory rheumatological disorders other than RA;
- •History of tuberculosis (TB) infection;
- •Pregnant or lactating women.
研究组 & 干预措施
GLPG0634 100 mg bid oral capsules
Experimental
干预措施: GLPG0634 (Drug)
GLPG0634 200 mg qd oral capsules
Experimental
干预措施: GLPG0634 (Drug)
Placebo oral capsules
Placebo Comparator
干预措施: GLPG0634 (Drug)
结局指标
主要结局
The number of patients with an ACR20 score at Week 4 as a measure of efficacy
时间窗: 4 weeks
To preliminarily evaluate the efficacy of GLPG0634 compared to placebo in terms of the proportion of subjects achieving an ACR20 response at Week 4
次要结局
- The number of patients with ACR20/50/70 response, time to response and DAS28 score at every visit as a measure of efficacy
- The number of patients with adverse events, abnormal lab tests, vital signs and ECG as a measure of safety and tolerability
- The plasma levels of GLPG0634 as a measure of PK and the levels of immune- and inflammation-related parameters in blood as a measure of PD
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Acute Response to Exercise in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT04927546University of Sao Paulo30
已完成
2 期
A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)Rheumatoid ArthritisNCT01285752Asahi Kasei Pharma Corporation240
Unknown
不适用
Biomarkers in Rheumatoid Arthritis Treated With Anti-interleukin-6 TherapyRheumatoid ArthritisNCT04281602University Hospital, Caen25
Unknown
4 期
Comparison of Adalimumab and Infliximab Treatment of Rheumatoid ArthritisRheumatoid ArthritisNCT00216177Hvidovre University Hospital112
终止
2 期
104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) ParticipantsRheumatoid ArthritisNCT00664573Biogen339